Drug uptake transporters in antiretroviral therapy.

Abstract:

:Current treatment of human immunodeficiency virus-1 (HIV-1) infection is effective, although it does not permanently suppress viral replication in all patients. Viral persistence, drug toxicity, and antiretroviral resistance are challenging barriers to successful treatment of HIV-1 infection. It has become increasingly apparent that the balance between drug influx and efflux transporter activity plays a critical role in the overall disposition of anti-HIV drugs in both cells and tissues. Thus, drug transporters directly influence the appearance of drug resistance and toxicity, and could also be related to persistence of HIV-1. We review the role of drug uptake transporters from the solute carrier (SLC) superfamily, their relation with specific antiretroviral drug disposition, and their efficacy in the tissues that absorb, metabolize, and eliminate anti-HIV drugs. Recent studies focusing on the role of drug uptake transporters in immune cells, key sites in the action of antiviral therapy, are highlighted.

journal_name

Pharmacol Ther

authors

Minuesa G,Huber-Ruano I,Pastor-Anglada M,Koepsell H,Clotet B,Martinez-Picado J

doi

10.1016/j.pharmthera.2011.06.007

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

268-79

issue

3

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(11)00159-8

journal_volume

132

pub_type

杂志文章,评审
  • The pharmacology of bitter taste receptors and their role in human airways.

    abstract::The receptors involved in bitter taste perception (bitter taste receptors--T2Rs) constitute a family of G-protein-coupled receptors, of which around 29 subtypes have been identified in humans. T2R expression was initially thought to be confined to the oral cavity but has recently been described in a range of other tis...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.08.001

    authors: Devillier P,Naline E,Grassin-Delyle S

    更新日期:2015-11-01 00:00:00

  • Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.

    abstract::Proteolytic degradation of unwanted proteins by the ubiquitin-proteasome system (UPS) is critical for normal maintenance of various cellular functions. Parkinson's disease (PD), one of the most prevalent neurodegenerative disorders, is characterized by prominent and irreversible nigral dopaminergic neuronal loss and i...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.04.001

    authors: Sun F,Kanthasamy A,Anantharam V,Kanthasamy AG

    更新日期:2007-06-01 00:00:00

  • Perinatal changes in pulmonary vascular endothelial function.

    abstract::The pulmonary endothelium plays a crucial role in lung development and function during the perinatal period. Its 2 most important functions at this time are to help reduce pulmonary vascular resistance (PVR) in order to permit the entire cardiac output to pass through the lungs for the first time and to facilitate the...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.06.016

    authors: Wojciak-Stothard B,Haworth SG

    更新日期:2006-01-01 00:00:00

  • The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.

    abstract::The cardiovascular system is highly organised in time; blood pressure (BP), heart rate (HR), peripheral resistance, pressure and the release/activity of vasodilating hormones all display pronounced circadian variations. Pathophysiological events within the cardiovascular system are also not random, as shown for instan...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.11.008

    authors: Lemmer B

    更新日期:2006-09-01 00:00:00

  • Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus.

    abstract::Nitric oxide (NO) formed via endothelial NO synthase (eNOS) and neuronal NO synthase (nNOS) plays crucial roles in the regulation of blood flow through vasodilatation and decreased vascular resistance in various organs and tissues. NO derived from eNOS also contributes to the inhibition of platelet aggregation, adhesi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.04.009

    authors: Toda N,Imamura T,Okamura T

    更新日期:2010-09-01 00:00:00

  • Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system.

    abstract::Cyclooxygenase (COX) enzymes, or prostaglandin-endoperoxide synthases (PTGS), are heme-containing bis-oxygenases that catalyze the first committed reaction in metabolism of arachidonic acid (AA) to the potent lipid mediators, prostanoids and thromboxanes. Two isozymes of COX enzymes (COX-1 and COX-2) have been identif...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.04.011

    authors: Hewett SJ,Bell SC,Hewett JA

    更新日期:2006-11-01 00:00:00

  • Orphan neuropeptides and receptors: Novel therapeutic targets.

    abstract::Neuropeptides are the largest class of intercellular signaling molecules, contributing to a wide variety of physiological processes. Neuropeptide receptors are therapeutic targets for a broad range of drugs, including medications to treat pain, addiction, sleep disorders, and nausea. In addition to >100 peptides with ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.11.006

    authors: Fricker LD,Devi LA

    更新日期:2018-05-01 00:00:00

  • Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis.

    abstract::Cardiovascular disease (CVD) continues to be a leading cause of death worldwide with atherosclerosis being the major underlying pathology. The interplay between lipids and immune cells is believed to be a driving force in the chronic inflammation of the arterial wall during atherogenesis. Atherosclerosis is initiated ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.08.012

    authors: Lacy M,Atzler D,Liu R,de Winther M,Weber C,Lutgens E

    更新日期:2019-01-01 00:00:00

  • Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.

    abstract::The selective 5-HT2C receptor agonist lorcaserin, in conjunction with lifestyle modification, was approved by the FDA in 2012 for weight management. It has been marketed in the US as Belviq® since 2013. This article provides a review of the preclinical and clinical pharmacology of lorcaserin, including its pharmacokin...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107417

    authors: Higgins GA,Fletcher PJ,Shanahan WR

    更新日期:2020-01-01 00:00:00

  • Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic mechanisms.

    abstract::gamma-Aminobutyric acid(A) (GABA(A)) receptors are ligand-gated ion channels that, predominantly, mediate inhibitory synaptic transmission in the CNS. These receptors are pentameric complexes that are comprised of subunits from several classes (alpha, beta, gamma, delta, ), with each class consisting of several isofor...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2003.12.001

    authors: Kumar S,Fleming RL,Morrow AL

    更新日期:2004-03-01 00:00:00

  • The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis.

    abstract::Decades of research have established that the biological functions of thyrotropin-releasing hormone (TRH) extend far beyond its role as a regulator of the hypothalamic-pituitary-thyroid axis. Gary et al. [Gary, K.A., Sevarino, K.A., Yarbrough, G.G., Prange, A.J. Jr., Winokur, A. (2003). The thyrotropin-releasing hormo...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.09.004

    authors: Kamath J,Yarbrough GG,Prange AJ Jr,Winokur A

    更新日期:2009-01-01 00:00:00

  • The role of amyloid beta peptide 42 in Alzheimer's disease.

    abstract::During the last 20 years, an expanding body of research has elucidated the central role of amyloid precursor protein (APP) processing and amyloid beta peptide (Abeta) production in the risk, onset, and progression of the neurodegenerative disorder Alzheimer's disease (AD), the most common form of dementia. Ongoing res...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.06.006

    authors: Findeis MA

    更新日期:2007-11-01 00:00:00

  • Death the Fas way: regulation and pathophysiology of CD95 and its ligand.

    abstract::Apoptotic cell death mediated by the members of the tumor necrosis factor receptor family is an essential process involved in the regulation of cellular homeostasis during development, differentiation, and pathophysiological conditions. Among the cell death receptors comprising the tumor necrosis factor receptor super...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(00)00096-6

    authors: Sharma K,Wang RX,Zhang LY,Yin DL,Luo XY,Solomon JC,Jiang RF,Markos K,Davidson W,Scott DW,Shi YF

    更新日期:2000-12-01 00:00:00

  • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

    abstract::Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as bio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107588

    authors: Kurnit KC,Avila M,Hinchcliff EM,Coleman RL,Westin SN

    更新日期:2020-09-01 00:00:00

  • Beta-N-acetylhexosaminidase: a target for the design of antifungal agents.

    abstract::This review provides biochemical, analytical, and biological background information relating to beta-N-acetylhexosaminidase (HexNAc'ase; EC 3.2.1.52) as an emerging target for the design of low-molecular-weight antifungals. The article includes the following: (1) a biochemical description of HexNAc'ase (reaction catal...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(97)00110-1

    authors: Horsch M,Mayer C,Sennhauser U,Rast DM

    更新日期:1997-10-01 00:00:00

  • Targeting PI3 kinase in cancer.

    abstract::The PI3K/Akt/mTOR pathway is the most frequently known activated aberrant pathway in human cancers. Pathologic activation can occur at multiple levels along the signaling pathway by a variety of mechanisms, including point mutations, amplifications, and inactivation of tumor suppressor genes. This pathway is also a kn...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.09.006

    authors: Bauer TM,Patel MR,Infante JR

    更新日期:2015-02-01 00:00:00

  • Pathophysiology and pharmacology of the cardiac "late sodium current.".

    abstract::The "late sodium current" (I(NaL)) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal I(NaL) enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfuncti...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.06.001

    authors: Zaza A,Belardinelli L,Shryock JC

    更新日期:2008-09-01 00:00:00

  • Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.

    abstract::Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors are a class of lipid-lowering medications, with a major activity on plasma cholesterol levels, now enjoying a vast popularity among physicians and patients. These drugs, affecting a very early and key step of sterol biosynthesis, differ to a large extent ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90031-8

    authors: Sirtori CR

    更新日期:1993-12-01 00:00:00

  • Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells.

    abstract::In the search for new approaches to cancer therapy, the first alkyllysophospholipid (ALP) analogs were designed and studied about two decades ago, either as potential immunomodulators or as antimetabolites of phospholipid metabolism. In the meantime, it has been demonstrated that they really act in this way. However, ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)00001-w

    authors: Brachwitz H,Vollgraf C

    更新日期:1995-04-01 00:00:00

  • The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.

    abstract::Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (S1P), play many important roles in cellular activities. Ceramide and sphingosine inhibit cell proliferation and induce cell apoptosis while S1P has the opposite effect. Maintaining a metabolic balance of sphingolipids is essential for...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.10.011

    authors: Zheng X,Li W,Ren L,Liu J,Pang X,Chen X,Kang,Wang J,Du G

    更新日期:2019-03-01 00:00:00

  • The role of flavonoids in autoimmune diseases: Therapeutic updates.

    abstract::Flavonoids are natural polyphenolic compounds which are included in a panoply of drugs and used to treat and/or manage human ailments such as metabolic, cardiovascular, neurological disorders and cancer. Thus, the purpose of this review is to emphasize the importance of flavonoids for the treatment of autoimmune disea...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.09.009

    authors: Rengasamy KRR,Khan H,Gowrishankar S,Lagoa RJL,Mahomoodally FM,Khan Z,Suroowan S,Tewari D,Zengin G,Hassan STS,Pandian SK

    更新日期:2019-02-01 00:00:00

  • Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.

    abstract::Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00015-9

    authors: Aihara T,Nakamura E,Amagase K,Tomita K,Fujishita T,Furutani K,Okabe S

    更新日期:2003-04-01 00:00:00

  • PICK1: a multi-talented modulator of AMPA receptor trafficking.

    abstract::AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor trafficking is a fundamental mechanism for regulating synaptic strength, and hence may underlie cellular processes involved in learning and memory. PICK1 (protein interacting with C-kinase) is a PDZ and BAR domain-containing protein that has rece...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.02.002

    authors: Hanley JG

    更新日期:2008-04-01 00:00:00

  • Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases.

    abstract::Nucleoside monophosphate kinases catalyze the reversible phosphotransferase reaction between nucleoside triphosphates and monophosphates, i.e., monophosphates are converted to their corresponding diphosphate form. These enzymes play an important role in the synthesis of nucleotides that are required for a variety of c...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(00)00048-6

    authors: Van Rompay AR,Johansson M,Karlsson A

    更新日期:2000-08-01 00:00:00

  • GPCR interacting proteins (GIP).

    abstract::G protein-coupled receptors (GPCR) interact not only with heterotrimeric G proteins but also with accessory proteins called GPCR interacting proteins (GIP). These proteins have important functions. They are implicated in GPCR targeting to specific cellular compartments, in their assembling into large functional comple...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2004.06.004

    authors: Bockaert J,Fagni L,Dumuis A,Marin P

    更新日期:2004-09-01 00:00:00

  • Role of pharmacotherapy in cardiac ion channelopathies.

    abstract::In the last decade, there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10%-15% of SCD occurs in the presence of structurall...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.09.002

    authors: El-Sherif N,Boutjdir M

    更新日期:2015-11-01 00:00:00

  • Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?

    abstract::In addition to their prominent roles in the control of reproduction, estrogens are important modulators of energy balance, as evident in conditions of deficiency of estrogens, which are characterized by increased feeding and decreased energy expenditure, leading to obesity. AMP-activated protein kinase (AMPK) is a ubi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.03.014

    authors: López M,Tena-Sempere M

    更新日期:2017-10-01 00:00:00

  • Therapeutic targets in pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension is a progressive, fatal disease. Current treatments including prostanoids, endothelin-1 (ET-1) antagonists, and phosphodiesterase (PDE) inhibitors, have sought to address the pulmonary vascular endothelial dysfunction and vasoconstriction associated with the condition. These treatments ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.10.002

    authors: Rhodes CJ,Davidson A,Gibbs JS,Wharton J,Wilkins MR

    更新日期:2009-01-01 00:00:00

  • Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy.

    abstract::Mechanistic insights of cancer immunology have led to the development of immune checkpoint blockade therapy (ICBT), which has elicited a remarkable clinical response in some cancer patients. Increasing evidence suggests that activation of oncogenic pathways, such as RAS/RAF/MAPK and PI3K signaling, impairs the antitum...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.07.004

    authors: Zhao X,Subramanian S

    更新日期:2018-01-01 00:00:00

  • Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

    abstract::Neutrophils form an essential part of innate immunity against infection. Cancer chemotherapy-induced neutropenia (CCIN) is a condition in which the number of neutrophils in a patient's bloodstream is decreased, leading to increased susceptibility to infection. Granulocyte colony-stimulating factor (GCSF) has been the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107403

    authors: Abdel-Azim H,Sun W,Wu L

    更新日期:2019-12-01 00:00:00